Identification of a low-risk luminal a breast cancer cohort that may not benefit from breast radiotherapy

Journal of Clinical Oncology

Volumn 33, Issue 18, 2015, Pages 2035-2040

  Liu, Fei Fei ^a   Shi, Wei ^a   Done, Susan J ^a   Miller, Naomi ^a   Pintilie, Melania ^a   Voduc, David ^e   Nielsen, Torsten O ^e   Nofech Mozes, Sharon ^b   Chang, Martin C ^c   Whelan, Timothy J ^d   Weir, Lorna M ^e   Olivotto, Ivo A ^e   McCready, David R ^a   Fyles, Anthony W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; AGE; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; EARLY CANCER; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IPSILATERAL BREAST RELAPSE; LOW RISK POPULATION; LUMINAL A BREAST CANCER; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; AGED; BREAST NEOPLASMS; FLUORESCENCE IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; TUMOR RECURRENCE;

AGED; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATIN-5; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84937129359     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.7999     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707-1716, 2011
2. Tinterri C, Gatzemeier W, Costa A, et al: Breast-conservative surgery with and without radiotherapy in patients aged 55-75 years with early-stage breast cancer: A prospective, randomized, multicenter trial analysis after 108 months of median follow-up. Ann Surg Oncol 21:408-415, 2014
3. Blamey RW, Bates T, Chetty U, et al: Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 49:2294-2302, 2013
4. Fyles AW, McCready DR, Manchul LA, et al: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963-970, 2004
5. Hughes KS, Schnaper LA, Bellon JR, et al: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 31:2382-2387, 2013
6. Potter R, Gnant M, Kwasny W, et al: Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 68:334-340, 2007
7. Carlson RW, Allred DC, Anderson BO, et al: Breast cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:122-192, 2009
8. Bellon JR, Harris EE, Arthur DW, et al: ACR Appropriateness Criteria® conservative surgery and radiation: Stage I and II breast carcinoma - Expert panel on radiation oncology: Breast. Breast J 17:448-455, 2011
9. Aebi S, Davidson T, Gruber G, et al: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22:vi12-vi24, 2011
10. Giordano SH: Radiotherapy in older women with low-risk breast cancer: Why did practice not change? J Clin Oncol 30:1577-1578, 2012
11. Dowsett M, Goldhirsch A, Hayes DF, et al: International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9:R81, 2007
12. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
13. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
14. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352, 2012
15. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
16. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
17. Voduc KD, Cheang MC, Tyldesley S, et al: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691, 2010
18. Millar EK, Graham PH, O'Toole SA, et al: Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701-4708, 2009
19. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750, 2009
20. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
21. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
22. Starczynski J, Atkey N, Connelly Y, et al: HER2 gene amplification in breast cancer: A rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol 137:595-605, 2012
23. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
24. Altman DG, McShane LM, Sauerbrei W, et al: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med 9:e1001216, 2012
25. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
26. Smith BD, Arthur DW, Buchholz TA, et al: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74:987-1001, 2009
27. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
28. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
29. Ignatiadis M, Sotiriou C: Luminal breast cancer: From biology to treatment. Nat Rev Clin Oncol 10:494-506, 2013
30. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
31. Cheang MC, van de Rijn M, Nielsen TO: Gene expression profiling of breast cancer. Annu Rev Pathol 3:67-97, 2008
32. Chia SK, Bramwell VH, Tu D, et al: A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18:4465-4472, 2012